MXPA05008785A - Esteres de polietilen glicol activados. - Google Patents

Esteres de polietilen glicol activados.

Info

Publication number
MXPA05008785A
MXPA05008785A MXPA05008785A MXPA05008785A MXPA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A
Authority
MX
Mexico
Prior art keywords
esters
oxalate
polyethylene glycol
carbonate
activated
Prior art date
Application number
MXPA05008785A
Other languages
English (en)
Inventor
Foe Siong Tjoeng
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA05008785A publication Critical patent/MXPA05008785A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

La presente invencion se refiere a la preparacion de esteres polietilenglicol carbonato activos utiles para la pegilacion de peptidos y proteinas biologicamente activos y farmaceuticamente utiles; la invencion implica el uso de esteres carbonato y oxalato activados en la formacion de esteres activos carbonato mixtos de polietilenglicol que despues reaccionan con un conector o directamente con un peptido proteina diana.
MXPA05008785A 2003-02-19 2004-02-13 Esteres de polietilen glicol activados. MXPA05008785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44835403P 2003-02-19 2003-02-19
PCT/IB2004/000424 WO2004074345A2 (en) 2003-02-19 2004-02-13 Carbonate esters of polyethylene glycol activated by means of oxalate esters

Publications (1)

Publication Number Publication Date
MXPA05008785A true MXPA05008785A (es) 2005-10-18

Family

ID=32908577

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008785A MXPA05008785A (es) 2003-02-19 2004-02-13 Esteres de polietilen glicol activados.

Country Status (9)

Country Link
US (1) US7094872B2 (es)
EP (1) EP1597299A2 (es)
JP (1) JP2006517995A (es)
AR (1) AR043216A1 (es)
BR (1) BRPI0407511A (es)
CA (1) CA2515612A1 (es)
MX (1) MXPA05008785A (es)
TW (1) TW200426155A (es)
WO (1) WO2004074345A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393638C (en) 1999-12-22 2009-10-20 Shearwater Corporation Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
ES2291613T3 (es) 2002-01-16 2008-03-01 Biocompatibles Uk Limited Conjugados de polimeros.
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
ITPD20040159A1 (it) * 2004-06-21 2004-09-21 Univ Degli Studi Trieste Derivati bifunzionali del polietilenglicole loro preparazione e uso.
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
JP2007209543A (ja) * 2006-02-09 2007-08-23 Hidetoshi Tsuchida 表面修飾アルブミンからなる固相膜および酸素吸着膜
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH07500315A (ja) * 1991-05-10 1995-01-12 セルトリックス　ファーマシューティカルズ，インコーポレイテッド 骨成長因子の標的送達
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
US20040162388A1 (en) 2004-08-19
BRPI0407511A (pt) 2006-02-14
EP1597299A2 (en) 2005-11-23
TW200426155A (en) 2004-12-01
WO2004074345A2 (en) 2004-09-02
WO2004074345A3 (en) 2005-01-20
JP2006517995A (ja) 2006-08-03
US7094872B2 (en) 2006-08-22
AR043216A1 (es) 2005-07-20
CA2515612A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
BRPI0406605B8 (pt) conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
EA200500644A1 (ru) Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
EP2517721A3 (en) Treatment of T-cell mediated diseases
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
WO2002055098A3 (en) Latency associated peptide for providing latency to pharmaceutically active proteins
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
DE60236796D1 (de) Verzweigte polyalkylenglykole
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
MXPA05008785A (es) Esteres de polietilen glicol activados.
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
EP2083018A3 (en) Compositions and methods relating to STOP-1
WO2006060021A3 (en) Bifunctional fusion proteins containing the flt3 ligand
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
WO2006103354A3 (fr) Composition dermatologique et/ou cosmetique contenant des proteines de la famille des sirt
WO2003017938A3 (en) Conjugates targeted to target receptors
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal